Gossamer Bio
GOSS
127 hedge funds and large institutions have $688M invested in Gossamer Bio in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 11 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
60% more capital invested
Capital invested by funds: $430M → $688M (+$257M)
10% more funds holding
Funds holding: 115 → 127 (+12)
2.11% more ownership
Funds ownership: 69.94% → 72.05% (+2.1%)
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
1% more call options, than puts
Call options by funds: $5.41M | Put options by funds: $5.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.23M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.92M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.79M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.12M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.98M |
| 3 |
Two Sigma Investments
New York
|
-$2.66M |
| 4 |
SCM
Sio Capital Management
New York
|
-$2.12M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
126
Sio Capital Management
New York
| – | -$2.12M | -261,400 | Closed |
|
|
FCM
127
Farallon Capital Management
San Francisco,
California
| – | -$1.64M | -202,326 | Closed |
|
|
CCP
128
Clough Capital Partners
Boston,
Massachusetts
| – | -$1.3M | -159,725 | Closed |
|
|
DY
129
Dowling & Yahnke
San Diego,
California
| – | -$776K | -95,575 | Closed |
|
130
Barclays
London,
United Kingdom
| – | -$109K | -13,429 | Closed |
|
131
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$108K | -13,271 | Closed |
|
132
Squarepoint
New York
| – | -$86K | -10,575 | Closed |
|
|
SM
133
SG3 Management
Dorado,
Puerto Rico
| – | -$16K | -2,000 | Closed |
|
|
CG
134
Cutler Group
San Francisco,
California
| – | -$12K | -1,500 | Closed |
|
|
SSB
135
Sandy Spring Bank
Olney,
Maryland
| – | -$2K | -300 | Closed |
|
136
Rockefeller Capital Management
New York
| – | +$37 | +4 | New |
|
|
QCG
137
Quadrant Capital Group
Cincinnati,
Ohio
| – | +$258 | +28 | New |
|
GOSS Hedge Fund Activity: Q3 2021 in Review
127 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q3 2021, worth a combined $688M — up 60% from $430M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GOSS positions and 11 closed out — a net gain of 12 holders — while 35 added to existing stakes and 32 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $14.5M. The largest seller was State Street, cutting an estimated $6.12M.
- 127 institutional investors held Gossamer Bio (GOSS) as of Q3 2021, up from 115 in Q2 2021.
- Funds reported $688M of Gossamer Bio stock for Q3 2021, up 60% quarter-over-quarter.
- 23 funds opened new Gossamer Bio positions in Q3 2021 and 11 closed out, a net change of +12 holders.
- The largest Gossamer Bio buyer in Q3 2021 was Citadel Advisors, an estimated $14.5M added.
- The largest Gossamer Bio seller in Q3 2021 was State Street, an estimated $6.12M sold.
Based on aggregated 13F filings for Q3 2021.